Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 2
2009 2
2010 3
2011 4
2012 3
2013 3
2014 4
2015 4
2016 2
2017 7
2018 9
2019 10
2020 13
2021 6
2022 8
2023 10
2024 9
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Alport Syndrome.
Chavez E, Goncalves S, Rheault MN, Fornoni A. Chavez E, et al. Among authors: rheault mn. Adv Kidney Dis Health. 2024 May;31(3):170-179. doi: 10.1053/j.akdh.2024.02.004. Adv Kidney Dis Health. 2024. PMID: 39004457 Review.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: rheault mn. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Among authors: rheault mn. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Effects of Bardoxolone Methyl in Alport Syndrome.
Warady BA, Pergola PE, Agarwal R, Andreoli S, Appel GB, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Kashtan CE, Knebelmann B, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Rheault MN, Silva AL, Stenvinkel P, Torra R, Chertow GM. Warady BA, et al. Among authors: rheault mn. Clin J Am Soc Nephrol. 2022 Dec;17(12):1763-1774. doi: 10.2215/CJN.02400222. Epub 2022 Nov 21. Clin J Am Soc Nephrol. 2022. PMID: 36411058 Free PMC article. Clinical Trial.
Genome-wide studies define new genetic mechanisms of IgA vasculitis.
Liu L, Zhu L, Monteiro-Martins S, Griffin A, Vlahos LJ, Fujita M, Berrouet C, Zanoni F, Marasa M, Zhang JY, Zhou XJ, Caliskan Y, Akchurin O, Al-Akash S, Jankauskiene A, Bodria M, Chishti A, Esposito C, Esposito V, Claes D, Tesar V, Davis TK, Samsonov D, Kaminska D, Hryszko T, Zaza G, Flynn JT, Iorember F, Lugani F, Rizk D, Julian BA, Hidalgo G, Kallash M, Biancone L, Amoroso A, Bono L, Mani LY, Vogt B, Lin F, Sreedharan R, Weng P, Ranch D, Xiao N, Quiroga A, Matar RB, Rheault MN, Wenderfer S, Selewski D, Lundberg S, Silva C, Mason S, Mahan JD, Vasylyeva TL, Mucha K, Foroncewicz B, Pączek L, Florczak M, Olszewska M, Gradzińska A, Szczepańska M, Machura E, Badeński A, Krakowczyk H, Sikora P, Kwella N, Miklaszewska M, Drożdż D, Zaniew M, Pawlaczyk K, SiniewiczLuzeńczyk K, Bomback AS, Appel GB, Izzi C, Scolari F, Materna-Kiryluk A, Mizerska-Wasiak M, Berthelot L, Pillebout E, Monteiro RC, Novak J, Green TJ, Smoyer WE, Hastings MC, Wyatt RJ, Nelson R, Martin J, González-Gay MA, De Jager PL, Köttgen A, Califano A, Gharavi AG, Zhang H, Kiryluk K. Liu L, et al. Among authors: rheault mn. medRxiv [Preprint]. 2024 Oct 11:2024.10.10.24315041. doi: 10.1101/2024.10.10.24315041. medRxiv. 2024. PMID: 39417133 Free PMC article. Preprint.
Treatment Approaches for Alport Syndrome.
Rheault MN. Rheault MN. J Am Soc Nephrol. 2025 Sep 12. doi: 10.1681/ASN.0000000897. Online ahead of print. J Am Soc Nephrol. 2025. PMID: 40938675
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha IL, Radhakrishnan J, Rheault MN, Rote W, Trachtman H, Trimarchi H, Perkovic V; PROTECT investigators. Barratt J, et al. Among authors: rheault mn. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180506 Free PMC article.
Hearing loss and renal syndromes.
Phelan PJ, Rheault MN. Phelan PJ, et al. Among authors: rheault mn. Pediatr Nephrol. 2018 Oct;33(10):1671-1683. doi: 10.1007/s00467-017-3835-9. Epub 2017 Nov 12. Pediatr Nephrol. 2018. PMID: 29130116 Review.
91 results